GENSCRIPT BIO(HK:01548) 第一财经·2025-10-16 08:55Core Insights - The article highlights the success of Carvykti (siltuximab), a CAR-T cell therapy developed by Legend Biotech, which has achieved over $1 billion in sales, marking it as a "blockbuster" drug in the biopharmaceutical industry [3][4]. Sales Performance - Carvykti's sales for Q3 reached $524 million, with cumulative sales for the year amounting to $1.332 billion, including $369 million in Q1 and $439 million in Q2 [3][4]. - The drug was first approved in the U.S. on February 28, 2022, and has since been approved in Japan, the EU, and China, although it has not yet been marketed in China [4]. Market Dynamics - In the Chinese market, there are currently seven CAR-T cell therapies approved, but high prices limit accessibility, with Carvykti priced at $555,300 in the U.S., significantly higher than the domestic CAR-T therapies priced over 1 million [4]. - The global sales of Carvykti are showing a stable growth trend, primarily in the multiple myeloma indication, where it has demonstrated significant efficacy [4][5]. Clinical Data - Recent long-term follow-up data from the CARTITUDE-1 study indicated that 33% of patients with relapsed or refractory multiple myeloma experienced no disease progression for five years after a single infusion of Carvykti, marking a significant advancement in treatment outcomes [5]. Financial Outlook - Legend Biotech is on track to turn a profit by 2026, following a net loss of approximately $101 million in Q1 2025, driven by the increasing sales of Carvykti [6][8].